Keywords: adventrx, sees, positive, ph, ii, cofactor, cancer
Adventrx sees positive Ph II CoFactor cancer trial data
Article | 06 February 2006
USA-based Adventrx Pharmaceuticals, a specialist developer of anticancer and antiviral drugs, has announced positive efficacy and safety data from Phase ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
